Your browser doesn't support javascript.
loading
A multicomponent smoking cessation program for adults with Type 2 Diabetes Mellitus (DiMe-SALUD2 project): A study protocol of a randomized controlled trial.
López-Núñez, Carla; Fernández-Artamendi, Sergio; Ruiz-Aranda, Desirée; Resurrección, Davinia María; Navas-Campaña, Desirée.
Afiliación
  • López-Núñez C; Department of Personality, Assessment and Psychological Treatments, School of Psychology, University of Seville, Seville (Andalusia), Spain.
  • Fernández-Artamendi S; Department of Personality, Assessment and Psychological Treatments, School of Psychology, University of Seville, Seville (Andalusia), Spain.
  • Ruiz-Aranda D; Department of Psychology, Universidad Loyola Andalucía, Seville (Andalusia), Spain.
  • Resurrección DM; Department of Psychology, Universidad Loyola Andalucía, Seville (Andalusia), Spain.
  • Navas-Campaña D; Department of Psychology, Universidad Loyola Andalucía, Seville (Andalusia), Spain.
Contemp Clin Trials Commun ; 41: 101361, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39290519
ABSTRACT

Background:

Tobacco use represents a significant public health burden, being especially harmful for smokers with Type 2 Diabetes Mellitus (T2DM). Effective smoking cessation interventions are required for this vulnerable population. The goal is to describe a study protocol of a randomized controlled trial (RCT) aimed at analyzing the effectiveness and efficiency of a multicomponent smoking cessation intervention for T2DM smokers, including a training protocol on healthy lifestyle habits and self-management of T2DM (DiMe-SALUD2 project).

Methods:

This RCT will assign participants to (1) Control Group (n = 30), including a brief psychoeducation advice about smoking cessation; (2) Cognitive-behavioral treatment (CBT) for smoking cessation (n = 30), based on a multicomponent program implemented in group-based sessions over an eight-week period; and (3) CBT plus DiMeSALUD2 protocol (n = 30), which will develop an additional psychoeducational protocol specifically designed to improve healthy lifestyle habits. Participants will be assessed at baseline, post-treatment and several follow-ups (1-, 6- and 12-months). Primary outcomes will include smoking abstinence (24-h point prevalence abstinence at post-treatment and 7-day point prevalence at follow-ups) and smoking continuous abstinence. Secondary outcomes will include treatment retention, changes in smoking patterns and nicotine dependence, as well as the impact on T2DM clinical variables, mental health, and quality of life.

Discussion:

The DiMeSALUD2 program could assist T2DM smokers in quitting tobacco use and improving their overall quality of life. This project will help incorporating improvements in routine clinical practice with T2DM patients, offering a smoking cessation program adapted to their specific needs. Trial registration ClinicalTrials.gov. Identifier NCT05885659. Date of registration June 2nd, 2023.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Contemp Clin Trials Commun Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Contemp Clin Trials Commun Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos